Public Meeting: FDA Rare Disease Day 2026 02 23 2026 FDA A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York 2024 FDA approvals exceed average number but have lower sales projections